WallStSmart

Cardio Diagnostics Holdings Inc (CDIO)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 15418585% more annual revenue ($2.23B vs $14,450). CDIO leads profitability with a 0.0% profit margin vs -141.4%. CDIO earns a higher WallStSmart Score of 23/100 (F).

CDIO

Avoid

23

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 2/9Altman Z: -1.93

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CDIOUndervalued (+40.5%)

Margin of Safety

+40.5%

Fair Value

$2.22

Current Price

$2.03

$0.19 discount

UndervaluedFair: $2.22Overvalued
MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CDIO2 strengths · Avg: 10.0/10
Price/BookValuation
0.8x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

CDIO4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$6.01M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CDIO

The strongest argument for CDIO centers on Price/Book, Debt/Equity.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : CDIO

The primary concerns for CDIO are EPS Growth, Market Cap, Profit Margin.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CDIO profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

CDIO carries more volatility with a beta of 2.23 — expect wider price swings.

MRNA is growing revenue faster at 2.1% — sustainability is the question.

CDIO generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

CDIO scores higher overall (23/100 vs 21/100). MRNA offers better value entry with a 70.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cardio Diagnostics Holdings Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cardio Diagnostics Holdings Inc (CDIO) is a pioneering biotechnology firm focused on enhancing cardiovascular health through innovative diagnostic solutions. The company utilizes state-of-the-art technology to equip healthcare professionals with vital tools for precise assessment and management of cardiovascular diseases, thereby improving patient outcomes. With a commitment to personalized medicine and a robust growth strategy, CDIO stands out as an attractive investment opportunity for institutional investors seeking to capitalize on advancements in the dynamic healthcare sector.

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?